Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zyomyx Launches its Protein Chip System: Why Measure Genes, When You Could Measure Actual Cytokines?

This article was originally published in Start Up

Executive Summary

Plenty of companies have tried to commercialize protein chips, but it's been very hard to do. Zyomyx believes it has overcome problems that flummoxed others. It has just launched a chip--and specialized reader system--that measures 30 human cytokines. In essence, the chip is a standard sandwich assay, only miniaturized. Zyomyx is hoping its ease of use will encourage people to test for cytokines in phases of drug discovery and development where that's never been possible before. The company believes that measuring proteins that are actually present at a given point in time, versus genes that may or may not be influential, will be of immediate practical value.

You may also be interested in...



Clinical Research Tools: A Special Situation for Venture Investors and Entrepreneurs

Five years after the genomics bubble burst and financing doors shut, a small window may be opening for research tool suppliers that help pharma improve R&D efficiency and cost structure. But clinically-oriented research companies face particular challenges, notably how to build a business where customer adoption is slow but technology is evolving rapidly and investors are impatient.

Clinical Research Tools: A Special Situation for Venture Investors and Entrepreneurs

Five years after the genomics bubble burst and financing doors shut, a small window may be opening for research tool suppliers that help pharma improve R&D efficiency and cost structure. But clinically-oriented research companies face particular challenges, notably how to build a business where customer adoption is slow but technology is evolving rapidly and investors are impatient.

Disco(very) Dancing to a Slower Beat?

SARS. Iraq. Recession. Terrorists. Risk aversion is in the air, and it hardly seems surprising that leading suppliers of discovery tools for studying gene expression are warning that their own businesses may suffer going forward. Roche and Merck say it's discovery-business-as-usual in Big Pharma, despite the fact that capital spending in the biotech sector has slowed. But some Wall Street analysts contend that customers are moving away from gene expression as a discovery vehicle. And such a point of view creates disturbing implications for the still unprofitable Affymetrix, which has yet to demonstrate that selling gene-based microarrays and related instrument systems is a model for a sustainable business.

Topics

Related Companies

UsernamePublicRestriction

Register

SC090732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel